All Stories

  1. Engineering Soluble Recombinant BCMA for Ide‐Cel Labeling
  2. Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis
  3. TNF receptor activation through pre-assembly and tonic signaling
  4. Protein-fragment complementation assays to analyze the CD95 complex
  5. Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders
  6. CD95/Fas stoichiometry in future precision medicine
  7. Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models
  8. Membrane‐bound CD95 ligand modulates CD19‐mediated B cell receptor signaling and EBV activation
  9. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways
  10. CD95L concatemers highlight different stoichiometries of CD95‐mediated apoptotic and non‐apoptotic pathways
  11. CD95L concatemers highlight difference in the manner CD95-mediated apoptotic and non-apoptotic pathways are triggered
  12. Ambivalent role of FasL in murine acute graft-versus-host-disease
  13. MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways
  14. Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network
  15. Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors
  16. Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii
  17. Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity
  18. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
  19. CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism
  20. CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
  21. Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipig
  22. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis
  23. Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation
  24. CD95 Structure, Aggregation and Cell Signaling
  25. Correction: CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
  26. Editor's Note: Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP
  27. The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
  28. Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction
  29. Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
  30. Correction: The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway
  31. Investigation of Phospholipase Cγ1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors
  32. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer
  33. HIV protease inhibitors and autoimmunity: An odd, but promising idea
  34. Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis
  35. CD95/Fas and metastatic disease: What does not kill you makes you stronger
  36. Staphylococcus aureus induces DNA damage in host cell
  37. An insight into the role of the death receptor CD95 throughout pregnancy: Guardian, facilitator, or foe
  38. Chemical Composition, Antioxidant, and Anticancer Effect of Ruta chalepensis’s Extracts against Human Leukemic Cells
  39. Disrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation
  40. Ovarian Cancer Immunity
  41. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
  42. Tumor analysis: freeze–thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells
  43. Nonapoptotic functions of Fas/CD95 in the immune response
  44. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases
  45. Chemical composition, antioxidant, and anticancer effect of Ruta chalepensis’s extracts against human leukemic cells
  46. FAS (Fas cell surface death receptor)
  47. T cell landscape in triple negative breast cancer patients
  48. Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L
  49. Erratum
  50. CD95
  51. CD95 Stimulation with CD95L and DISC Analysis
  52. Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition
  53. Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K
  54. Atypical Immune Functions of CD95/CD95L
  55. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress
  56. Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?
  57. How mTOR inhibitors show some success in clinical trials
  58. Cyaneodimycin, a Bioactive Compound Isolated from the Culture ofStreptomyces cyaneofuscatusAssociated withLichina confinis
  59. CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice
  60. The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca2+ flux from the endoplasmic reticulum to mitochondria
  61. The cleaved FAS ligand activates the Na+/H+ exchanger NHE1 through Akt/ROCK1 to stimulate cell motility
  62. Sphingolipids modulate the epithelial–mesenchymal transition in cancer
  63. Meet Our Editorial Board Member:
  64. Chemotherapy with ceramide in TNBC
  65. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
  66. The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis
  67. The CD95/CD95L signaling pathway: A role in carcinogenesis
  68. Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility
  69. CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
  70. Staphylococcus aureus-Induced G2/M Phase Transition Delay in Host Epithelial Cells Increases Bacterial Infective Efficiency
  71. Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity
  72. Precise Mapping of the CD95 Pre-Ligand Assembly Domain
  73. Guidelines for the use and interpretation of assays for monitoring autophagy
  74. The CD95 signaling pathway
  75. CD95 triggers Orai1-mediated localized Ca2+entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation
  76. CD95-mediated cell signaling in cancer: mutations and post-translational modulations
  77. Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre and Faustino Mollinedo)]
  78. Actin-independent exclusion of CD95 by PI3K/AKT signalling: Implications for apoptosis
  79. Does calcium contribute to the CD95 signaling pathway?
  80. The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway
  81. S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand–Mediated Apoptosis in Cancer Cells
  82. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells
  83. Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
  84. CD95 engagement mediates actin-independent and -dependent apoptotic signals
  85. The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells
  86. An atypical necrotic signal induced by immunosuppressive and anti-viral agents
  87. Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway
  88. Rewinding the DISC
  89. The HA tag is cleaved and loses immunoreactivity during apoptosis
  90. Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP
  91. Corrigendum to “Does CD95 have tumor promoting activities?” [Biochim. Biophys. Acta 1755 (2005) 25–36]
  92. Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment
  93. Does CD95 have tumor promoting activities?
  94. Induction of apoptosis and activation of NF‐κB by CD95 require different signalling thresholds
  95. The relevance of NF-?B for CD95 Signaling in Tumor Cells
  96. Identification of SNF1/AMP Kinase-related Kinase as an NF-κB-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness
  97. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells
  98. Two CD95 tumor classes with different sensitivities to antitumor drugs
  99. Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism
  100. Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas